Form D · Biotechnology
Avirmax, Inc.
Hayward, CA · CIK 0001795165
Offering snapshot reported Nov 26, 2019 · SEC filing
- Reported sold
- $3M Offering amount: $10M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 18, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 26, 2019 | Initial | $2,999,999 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-354271
Source: Form D, filed Nov 26, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Nancy Chang | Director |
| Haifeng Chen | Director, Executive |
| Yu Fang | Director |
| Shengjiang Liu | Director, Executive |
| Qianye Karen Liu | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
22421 Hesperian Blvd.
Hayward, CA, 94541
Hayward, CA, 94541